.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Cipla
Queensland Health
Harvard Business School
Dow
Merck
Novartis
Fuji
AstraZeneca
Cerilliant

Generated: January 23, 2018

DrugPatentWatch Database Preview

Patents Expiring in December 2032

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Fresenius Kabi UsaCASPOFUNGIN ACETATEcaspofungin acetatePOWDER;IV (INFUSION)206110-001Dec 30, 2016APRXNoNo➤ Subscribe➤ SubscribeY
Fresenius Kabi UsaCASPOFUNGIN ACETATEcaspofungin acetatePOWDER;IV (INFUSION)206110-002Dec 30, 2016APRXNoNo➤ Subscribe➤ SubscribeY
Eisai IncBELVIQlorcaserin hydrochlorideTABLET;ORAL022529-001Jun 27, 2012RXYesYes➤ Subscribe➤ SubscribeUSE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
Eisai IncBELVIQlorcaserin hydrochlorideTABLET;ORAL022529-001Jun 27, 2012RXYesYes➤ Subscribe➤ SubscribeUSE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
Eisai IncBELVIQlorcaserin hydrochlorideTABLET;ORAL022529-001Jun 27, 2012RXYesYes➤ Subscribe➤ SubscribeUSE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
Eisai IncBELVIQlorcaserin hydrochlorideTABLET;ORAL022529-001Jun 27, 2012RXYesYes➤ Subscribe➤ SubscribeUSE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
Eisai IncBELVIQ XRlorcaserin hydrochlorideTABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYesYes➤ Subscribe➤ Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
UBS
Covington
Merck
US Department of Justice
Federal Trade Commission
Baxter
Express Scripts
Mallinckrodt
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot